Navigation Links
B cells are required for development of epithelial cancer associated with chronic inflammation

Chronic inflammation is linked to the development of certain types of cancer, but mechanisms mediating inflammation during premalignancy are not well understood. A new research study published in the May issue of Cancer Cell identifies B lymphocytes as important regulators of premalignancy associated with chronic inflammation. The results suggest that drugs targeted against B lymphocytes or recruitment of innate immune cells toward premalignant tissue may represent a viable strategy to protect against the development of cancer in tissues identified as "at risk" due to chronic inflammation.

Previous studies have implicated an interaction between adaptive immune cells, like B lymphocytes, and innate immune cells during chronic inflammatory diseases. Dr. Lisa M. Coussens and colleagues from the Cancer Research Institute at the University of California at San Francisco used a mouse model of inflammation-associated skin cancer to study the roles and interactions of these different white blood cells in the progression of cancer.

The mice used in the study, called HPV16 mice, developed premalignant skin that was characterized by infiltration of innate immune cells. Genetic elimination of T and B lymphocytes in this model system resulted in a failure to recruit innate white blood cells to premalignant skin and an absence of chronic inflammation. As a consequence, parameters of early cancer development were attenuated, and cancer incidence was significantly reduced. The researchers went on to show that transfer of B cells or even just serum from regular HPV16 mice into the lymphocyte-deficient HPV16 mice restored chronic inflammation in premalignant skin and reinstated mechanisms necessary for tumorigenesis, like blood vessel development (angiogenesis) and enhanced skin cell proliferation.

These findings support the idea that the adaptive immune system interacts with the innate immune system during cancer development. "Together, these data indicate tha t peripheral B cell activation is an essential step for early epithelial neoplastic development, and B cell-derived soluble mediators are necessary for establishing chronic inflammatory states that potentiate cancer development," explains Dr. Coussens. "Pharmacological interventions attenuating B cell activation or blocking B cell-mediated recruitment of innate immune cells may be effective in preventing premalignant progression."

###

The researchers include Karin E. de Visser, Lidiya V. Korets, and Lisa M. Coussens of the University of California, San Francisco. K.E.d.V. is supported by a fellowship from the Dutch Cancer Society. L.M.C. is supported by grants from the NIH, NCI, and Department of Defense.

de Visser, K.E., Korets, L.V., and Coussens, L.M. (2005). De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411?23. www.cancercell.org


'"/>

Source:Cell Press


Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. Spleen may be source of versatile stem cells
3. Researchers discover way to make cells in the eye sensitive to light
4. Priming embryonic stem cells to fulfill their promise
5. Lack of enzyme turns fat cells into fat burners
6. Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas
7. Elusive HIV shape change revealed; Key clue to how virus infects cells
8. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
9. Enzyme allows B cells to resist death, leading to leukemia
10. Scientists rid stem cell culture of key animal cells
11. Genetically modified natural killer immune cells attack, kill leukemia cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... Calif. , March 22, 2017  UBM ... proud to announce their extended partnership and the ... be headlined by the 21 st Annual ... Boston, taking place May 3-4, 2017. ... Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced ... of their live events series, “Stem Cell Therapy: The Next Phase in the Evolution ... 2013 Stem Cell Research and Therapy Act, Okyanos maintains a mission to ...
Breaking Biology Technology: